Abstract
Five hundred and ninety two patients attending a psychiatric department as outpatients or as inpatient were included in this study. Details regarding age, sex, diagnosis and drugs prescribed were entered in a proforma. The information regarding drugs prescribed, dosage and the types of reactions were noted. All patients were followed up for a period of 3 to 4 weeks. Incidence of adverse reactions was calculated as percentage of the total number of prescriptions of the same group of drugs. The incidence of reactions to antipsychotic and antidepressants ranged from 35 to 46.9%. The incidence of reactions to haloperidol was higher than the reactions to other drugs. Antianxiety drugs were found to produce only minimal reactions. Two or more drugs prescribed together was associated with a higher incidence of reactions. Among the 193 patients who were reported to have reactions, 65.8% had extrapyramidal symptoms. The frequency of these reactions were highest with antipsychotic drugs haloperidol, chlorpromazine, trifluoperazine and thioridazine in that order. Dystonic reactions were reported within one to two days after the initiation of therapy in a large group of patients. Anticholinergic side effects were associated with prescription of tricyclic antidepressants andphenothiazines. Drowsiness, giddiness and postural hypotension were the other reactions associated with tricyclics.
Keywords: adverse reactions, psychopharmacological agents
Full Text
The Full Text of this article is available as a PDF (254.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Addonizio G., Roth S. D., Stokes P. E., Stoll P. M. Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis. 1988 Nov;176(11):682–685. doi: 10.1097/00005053-198811000-00006. [DOI] [PubMed] [Google Scholar]
- Barach E., Dubin L. M., Tomlanovich M. C., Kottamasu S. Dystonia presenting as upper airway obstruction. J Emerg Med. 1989 May-Jun;7(3):237–240. doi: 10.1016/0736-4679(89)90352-1. [DOI] [PubMed] [Google Scholar]
- Chaturvedi S. K. Adverse drug reactions--an epidemiological study at psychiatric hospitals. Acta Psychiatr Scand. 1985 Feb;71(2):204–205. doi: 10.1111/j.1600-0447.1985.tb01273.x. [DOI] [PubMed] [Google Scholar]
- Grohmann R., Hippius H., Müller-Oerlinghausen B., Rüther E., Scherer J., Schmidt L. G., Strauss A., Wolf B. Assessment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol. 1984;26(6):727–734. doi: 10.1007/BF00541933. [DOI] [PubMed] [Google Scholar]
- Grohmann R., Hippius H., Müller-Oerlinghausen B., Rüther E., Scherer J., Schmidt L. G., Strauss A., Wolf B. Assessment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol. 1984;26(6):727–734. doi: 10.1007/BF00541933. [DOI] [PubMed] [Google Scholar]
- Hermesh H., Shalev A., Munitz H. Contribution of adverse drug reaction to admission rates in an acute psychiatric ward. Acta Psychiatr Scand. 1985 Jul;72(1):104–110. doi: 10.1111/j.1600-0447.1985.tb02578.x. [DOI] [PubMed] [Google Scholar]
- Leber P. Adverse drug reactions--vital statistics (unavailable, yet essential). Psychopharmacol Bull. 1983 Spring;19(2):254–257. [PubMed] [Google Scholar]
- Murphy D. J., Gannon M. A., Hartman M. L. Extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis. 1989 Nov;177(11):708–708. doi: 10.1097/00005053-198911000-00016. [DOI] [PubMed] [Google Scholar]
- Schmidt L. G., Grohmann R., Helmchen H., Langscheid-Schmidt K., Müller-Oerlinghausen B., Poser W., Rüther E., Scherer J., Strauss A., Wolf B. Adverse drug reactions. An epidemiological study at psychiatric hospitals. Acta Psychiatr Scand. 1984 Jul;70(1):77–89. doi: 10.1111/j.1600-0447.1984.tb01185.x. [DOI] [PubMed] [Google Scholar]
- Weiden P., Bruun R. Worsening of Tourette's disorder due to neuroleptic-induced akathisia. Am J Psychiatry. 1987 Apr;144(4):504–505. doi: 10.1176/ajp.144.4.504. [DOI] [PubMed] [Google Scholar]
- Zito J. M., Craig T. J. Pharmacoepidemiologic methods for identifying and quantifying behavioral effects of neuropharmacological agents. Drug Intell Clin Pharm. 1988 Mar;22(3):260–266. doi: 10.1177/106002808802200319. [DOI] [PubMed] [Google Scholar]